



Welcome and thank you for your interest in *DrugReimbursement.com!*

DrugReimbursement.com is a comprehensive online application service that delivers search capability on essential FDA-approved drugs and related medical codes (CPT® codes, HCPCS Level II, NDCs), billing, coverage and reimbursement information. The drug coding and reimbursement database provides the most up-to-date reimbursement information for the HCPCS A, J, K, L and S, and the CPT® drug codes.

[Next
Feature](#)

The screenshot shows the website's main interface. At the top, there is a search bar with a dropdown menu set to 'Drug/Description' and a search button. To the right of the search bar are radio buttons for search criteria: 'Starts With', 'Contains', and 'Exact'. The left sidebar contains a 'User Info' section for 'Carol Endahl' with links for 'Edit Profile', 'Edit Preferences', and 'Logout'. Below this is a 'Subscriptions' list including 'UBEditor Pro', 'LMRP Plus', 'Chargemaster Analyzer', and 'Drug Reimbursement.com'. There is also a 'Previous Searches' section showing 'None' and a 'Links' section with 'Add to Favorites' and 'User Manual (pdf)'. The main content area features a 'What's New?' section with two identical news items dated 01/06/2005, each titled 'Find drug by manufacturer name' and containing the text: 'With DrugReimbursement.com, you are able to enter a full or partial manufacturer name into the search box and find all drugs by that manufacturer...wow!'. Below this is another news item dated 01/05/2005 titled 'Welcome to DrugReimbursement.com!' with the text: 'You are one of the lucky people who has the privilege of seeing the fabulous all-new product from Ingenix...DrugReimbursement.com! Count yourself lucky.'. At the bottom of the main content area is a 'DrugReimbursement.com News' section with the text 'News from UBEditor Pro (Super User)'. The footer contains copyright information: '© Copyright Ingenix, Inc. 2005. All Rights Reserved. CPT only © 2004 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association.'

© Copyright Ingenix, Inc. 2005. All Rights Reserved. CPT only © 2004 American Medical Association. All Rights Reserved.
CPT is a registered trademark of the American Medical Association.



Simplify Drug Searches

Flexible search capabilities allow you to quickly search for drugs by CPT® code, HCPCS Level II code, NDC, drug name (brand or generic) and by manufacturer.


[Previous Feature](#)

Eliminate time wasted looking up drugs and drug codes found in the code books or complex data tables. The **DrugReimbursement.com** search engine delivers search capability on essential FDA-approved drugs, and related medical codes using terms, acronyms or abbreviations. The search function provides access to detailed drug coding information and related Medicare reference and coverage edits.

[Next Feature](#)

The screenshot shows a search results page on DrugReimbursement.com. The search criteria are HCPCS/CPT Code: 90632. The search is performed using the 'Starts With' filter. The results table lists 10 entries for HEPATITIS A VACCINE, INACTIV 1440 UNT, with various NDC numbers and manufacturers.

Code	NDC	Generic Name	Brand Name	Strength	Unit	Manufacturer
90632	0007-0835-07	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	EL U /ML	SMITHKLINE BEECHAM PHARMACEUTICALS DIV SMITHKLINE BEECHAM CO
90632	58160-835-05	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	ELU/ML	GLAXOSMITHKLINE BIOLOGICALS SA
90632	58160-835-46	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	ELU/ML	GLAXOSMITHKLINE BIOLOGICALS SA
90632	58160-835-07	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	ELU/ML	GLAXOSMITHKLINE BIOLOGICALS SA
90632	58160-835-01	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	ELU/ML	GLAXOSMITHKLINE BIOLOGICALS SA
90632	58160-835-02	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	ELU/ML	GLAXOSMITHKLINE BIOLOGICALS SA
90632	0007-0835-46	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	EL U /ML	SMITHKLINE BEECHAM PHARMACEUTICALS DIV SMITHKLINE BEECHAM CO
90632	0007-0835-01	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	EL U /ML	SMITHKLINE BEECHAM PHARMACEUTICALS DIV SMITHKLINE BEECHAM CO
90632	0007-0835-41	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	EL U /ML	SMITHKLINE BEECHAM PHARMACEUTICALS DIV SMITHKLINE BEECHAM CO
90632	58160-835-41	HEPATITIS A VACCINE, INACTIV 1440 UNT	HAVRIX HEPATITIS A VACCINE INACTIVATED	1440	ELU/ML	GLAXOSMITHKLINE BIOLOGICALS SA

DrugReimbursement.com 

Manufacturer: Search Starts With Contains Exact

Manufacturer Search Results

▼ To Bottom: 55154-5595-0 - 64566-0002-2 1 2 3 4 5 6 7 8 9 10 ▶▶

Code	NDC	Generic Name	Brand Name	Strength	Unit	Manufacturer
	55154-5595-0	ACYCLOVIR 200 MG	ACYCLOVIR CAPSULES	200	MG	CARDINAL HEALTH
	55154-5595-7	ACYCLOVIR 200 MG	ACYCLOVIR CAPSULES	200	MG	CARDINAL HEALTH
J7608	55154-5730-0	ACETYL CYSTEINE 100 MG	ACETYL CYSTEINE SOLUTION 10 PERCENT	100	MG/ML	CARDINAL HEALTH
J7608	55154-5731-5	ACETYL CYSTEINE 200 MG	ACETYL CYSTEINE SOLUTION	20	%	CARDINAL HEALTH
	55154-0706-7	ACYCLOVIR 200 MG	ZOVIRAX CAPSULES	200	MG	CARDINAL HEALTH
	55154-0706-0	ACYCLOVIR 200 MG	ZOVIRAX CAPSULES	200	MG	CARDINAL HEALTH
	55154-1103-1	ALBUTEROL SULFATE NS	VENTOLIN TABLETS	4	MG	CARDINAL HEALTH
J7611	55154-4350-5	ALBUTEROL SULFATE 3 MG	ALBUTEROL SULFATE INHALATION SOLUTION	2.5	MG/ML	CARDINAL HEALTH
	55154-4304-1	ALBUTEROL SULFATE 4.8 MG	VOLMAX TABLETS EXTENDED RELEASE	4	MG	CARDINAL HEALTH
J0205	55154-1060-1	ALGLUCERASE 400 UNT	CEREDASE SOLUTION FOR INJECTION	400	UNT/10 ML	CARDINAL HEALTH

©Copyright Ingenix, Inc. 2005. All Rights Reserved. CPT only © 2004 American Medical Association. All Rights Reserved.
CPT is a registered trademark of the American Medical Association.



Code Detail

[Previous Feature](#)

Reduce research time and improve billing accuracy by understanding quickly whether a code carries an edit or is covered by Medicare. Coding guidelines, HCPCS annotations and CPT® code section notes and lay descriptions are attached appropriately to every code to help you select the correct codes quickly. Special icons alert you to new, revised, or deleted codes and quality issues.

[Next Feature](#)

The screenshot displays the 'CPT Code Detail - 90632' page. At the top, there is a search bar with a dropdown menu for 'Drug/Description' and a 'Search' button. To the right of the search bar are radio buttons for 'Starts With', 'Contains', and 'Exact'. The main content area is divided into two columns. The left column contains 'Medicare Reference Information' with sub-sections for 'Medicare Coverage Policies' (listing LCD, LMRP, and NCD) and 'Pub-100 References' (listing 100-2.15.50 and 100-2.16.90). The right column contains the code '90632' with its description 'Hepatitis A vaccine, adult dosage, for intramuscular use'. Below this are 'Code-Specific Edits' (Modifier -51 Exempt, APC Status N, Pub-100 References) and 'Notes' (Section Notes, AMA CPT Assistant References, Primary P). A 'Lay Descriptions' section follows, explaining the use of codes 90632, 90633, and 90634. At the bottom, there is a 'Section Notes - Vaccines, Toxoids - (90476-90749)' section with specific reporting instructions. The footer includes 'Contact Us | AMA Copyright | Terms of Use', copyright information for Ingenix, Inc. (2005) and the American Medical Association (2004), and a note that the content is 'CPT Only'.

DrugReimbursement.com ingenix

Drug/Description Search Starts With Contains Exact

CPT Code Detail - 90632

Medicare Reference Information

Medicare Coverage Policies

- ▶ LCD
- ▶ LMRP
- ▶ NCD

Pub-100 References

- ▶ 100-2.15.50
- ▶ 100-2.16.90

90632
Hepatitis A vaccine, adult dosage, for intramuscular use

Code-Specific Edits

- Modifier -51 Exempt
- APC Status N
- Pub-100 References

Notes

- ▶ Section Notes
- ▶ [AMA CPT Assistant References](#)
- ▶ [Primary P](#)



Lay Descriptions

These codes are used to report a hepatitis A vaccine for intramuscular use, prepared in various dosages. The vaccine is prepared from the blood plasma of asymptomatic human carriers of hepatitis caused by the hepatitis A virus or through recombinant DNA technology. Report [90632](#) for an adult dosage; report [90633](#) for a 2-dose schedule for a pediatric/adolescent dosage, and [90634](#) for a 3-dose schedule for pediatric/adolescent dosage. Report these codes with the appropriate administration code, [90471-90472](#).

Section Notes - Vaccines, Toxoids - (90476-90749)

Report codes [90476-90748](#) to recognize only the vaccine product. To report the administration of a vaccine/toxoid, the vaccine/toxoid product codes [90476-90749](#) must be used in addition to an immunization administration code(s) [90465-90474](#). Do not report modifier 51 to the vaccine/toxoid product code ([90476-90749](#)).

[Contact Us](#) | [AMA Copyright](#) | [Terms of Use](#)
© Ingenix, Inc. 2005. All Rights Reserved.
CPT Only © 2004 American Medical Association. All Rights Reserved.

DrugReimbursement.com  

Drug/Description Search Starts With Contains Exact

HCPCS Code Detail - J0150

<p>Medicare Reference Information</p> <p>Medicare Coverage Policies</p> <ul style="list-style-type: none"> ▶ LCD ▶ LMRP ▶ NCD <p>Pub-100 References</p> <ul style="list-style-type: none"> ▶ 100-2.15.50 	<p>J0150</p> <p>Injection, adenosine for therapeutic Use, 6 mg (not to be used to report any adenosine phosphate compounds, instead Use A9270)</p> <p>Code-Specific Edits</p> <ul style="list-style-type: none"> <input type="checkbox"/> Pub-100 References <input type="checkbox"/> Revised Code <input checked="" type="checkbox"/> Quantity Alert <p>Notes</p> <ul style="list-style-type: none"> ▶ Section Notes <p>Annotations</p> <p>Use this code for Adenocard.</p>
---	--

Section Notes - Drugs Administered Other Than Oral Method - (J0120-J8999)

J codes include drugs that ordinarily cannot be self-administered, chemotherapy drugs, immunosuppressive drugs, inhalation solutions, and other miscellaneous drugs and solutions

Section Notes - Exception: Oral Immunosuppressive Drugs - (J0120-J3590)

J codes fall under the jurisdiction of the DME Regional office for Medicare, unless incidental or otherwise noted.

[Contact Us](#) | [AMA Copyright](#) | [Terms of Use](#)
 © Ingenix, Inc. 2005. All Rights Reserved.
 CPT Only © 2004 American Medical Association. All Rights Reserved.

©Copyright Ingenix, Inc. 2005. All Rights Reserved. CPT only © 2004 American Medical Association. All Rights Reserved.
 CPT is a registered trademark of the American Medical Association.



Medical Necessity


Everyone in care delivery should be aware of medical necessity, particularly when treating Medicare patients.

Each affected code alerts you with an LMRP, LCD, or NCD indicator so that you may check drug codes for Medicare coverage instructions and medical necessity edits under Part A or Part B coverage. Understand which ICD-9-CM procedures define medical necessity and what the documentation guidelines are for successful claim submission. Gain insight into those drugs that carry little or discretionary coverage and how to report them.

[Previous
Feature](#)

[Next
Feature](#)

Some drugs are considered self-administered by patients and therefore, are not covered under Medicare Part B. **DrugReimbursement.com** helps you identify self-administrable drugs that are not covered under Medicare and should be billed to the patient.

DrugReimbursement.com 

Drug/Description Search Starts With Contains Exact

HCPCS Code Detail - J0150

Medicare Reference Information **J0150**
 Injection, adenosine for therapeutic Use, 6 mg (not to be used to report any adenosine phosphate compounds, instead Use A9270)



Medicare Coverage Policies
 ▶ LCD
 ▶ LMRP
 ▶ NCD

Pub-100 References
 ▶ 100-2.15.50

Section Notes - Drugs Administered
 J codes include drugs that ordinarily cannot be administered in solution

Section Notes - Exception: Oral Implants
 J codes fall under the jurisdiction of the D codes

Part A for J0150
 WT - Bonus

CMS ID	Title	Codes	Contractor Type	Contractor Name
L13121	Off-Label Coverage of FDA Approved Drugs and Biologicals		FI	00390 - BlueCross BlueShield of Tennessee (Riverbend Go...)
L13243	Adenosine (Adenocard)		FI	00390 - BlueCross BlueShield of Tennessee (Riverbend Go...)

Revision: 09/30/2003
 Effective Date:
 Revision Ending Date:
 LMRP Description:
 Adenosine is an endogenous nucleoside occurring in all cells of the body. It is produced in the blood vessels, heart and skeletal muscle, and other organs. Adenosine helps protect the heart muscle from damage when myocardial ischemia occurs. It can slow conduction time through the A-V node, can interrupt the reentry pathways through the AV-node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome. Adenosine is an antiarrhythmic drug that is not chemically related to other antiarrhythmic drugs. It is a sterile solution for rapid bolus intravenous injection that should be administered either directly into a vein or, if given into an IV line, it should be given as close to the patient as possible and followed by a rapid saline flush. Adenosine is removed from the circulation very rapidly with a half-life estimated to be less than 10 seconds. Adenosine is also used as a diagnostic aid in noninvasive testing in conjunction with myocardial perfusion scans for patients with suspected or known coronary artery disease.

Indications and Limitations of Coverage and/or Medical Necessity:

Indications:
Intravenous adenosine is indicated for:

- Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). The recommended intravenous dose for adults is an initial dose of 6 mg given as a rapid intravenous bolus (administered over a 1-2 second period). If the first dose does not result in elimination of the supraventricular tachycardia within 1-2 minutes, 12 mg should be given as a rapid intravenous bolus. This 12 mg dose may be repeated a second time if required. Doses greater than 12 mg are not recommended. When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration.
- As an adjunct to noninvasive testing in conjunction with myocardial perfusion scans to produce pharmacologic stress in those patients who are unable to exercise adequately (i.e., the inability to obtain 75-100% of their age-predicted heart rate through exercise). Examples of patients who may be unable to exercise include, but are not limited to

1 - 2 of 2

©Copyright Ingenix, Inc. 2005. All Rights Reserved. CPT only © 2004 American Medical Association. All Rights Reserved.
 CPT is a registered trademark of the American Medical Association.



Improve Billing and Chargemaster Accuracy

Using correct HCPCS codes when filing claims is the key to ensuring that your hospital/health system will receive the correct payment from Medicare.

DrugReimbursement.com provides complete, up-to-date crosswalk of approved national drug codes (NDCs) to CMS-billable drug codes and helps you correctly determine billable units and billing NDCs.

[Previous Feature](#)

[Next Feature](#)

Detailed drug data identifies packaging and billable unit variations, and provides link to national and local coverage issues, billing guidelines and fraud alerts.

0469-0872-02 - ADENOCARD INJECTION SOLUTION	
Drug Information	
Generic Name:	ADENOSINE 3 MG
Brand Name:	ADENOCARD INJECTION SOLUTION
NDC Code:	0469-0872-02
Billing NDC Code:	00469-0872-02
OPPS Code:	C9223
HCPCS/CPT Code:	J0150
Description:	Injection, adenosine for therapeutic Use, 6 mg (not to be used to report any adenosine phosphate compounds, instead Use A9270)
Annotation:	Use this code for Adenocard.
Route:	INTRAVENOUS
Unit:	MG/ML
Form of Administration:	INJ SOL
Strength:	3
RX or OTC:	R
Billable Units Per Package:	10
Billable Units Per NDC:	10
NCD Manual Reference:	
Deactivated:	false
Manufacturer:	FUJISAWA HEALTHCARE INC

©Copyright Ingenix, Inc. 2005. All Rights Reserved. CPT only © 2004 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association.



Improve Drug Cost Management

[Previous Feature](#)

Current Medicare ASP and APC drug pricing information helps you monitor drug charges, costs, and expected Medicare reimbursement.

Payment - 68839-100-02 - F 18 FLUDEOXYGLUCOSE INJECTION SOLUTION

Part B Payment	OPPS Payment
APC Group:	1775
OPPS Payment:	\$221.11
Min. Unadjusted Copayment:	\$44.22
OPSI Code:	K
OPSI Change Date:	03/31/1998
OPSI Description:	Non Pass-Through Drug/Biological, Radiopharmaceutical Agents
OPPS Effective Date:	12/31/1999
OPPS Delete Date:	

[Contact Us](#) | [AMA Copyright](#) | [Terms of Use](#)
 © Ingenix, Inc. 2005. All Rights Reserved.
 CPT Only © 2004 American Medical Association. All Rights Reserved.

Payment - 46331-015-02 - ANTIRABIES SERUM EQUINE PURIFIED

Part B Payment	OPPS Payment	Other Payment
Average Sales Price (ASP):		
Medicare Payment Allowance Limit:	\$63.38	
Payment Limit Effective Date:	04/01/2005	

[Contact Us](#) | [AMA Copyright](#) | [Terms of Use](#)
 © Ingenix, Inc. 2005. All Rights Reserved.
 CPT Only © 2004 American Medical Association. All Rights Reserved.

Payment - 46331-015-02 - ANTIRABIES SERUM EQUINE PURIFIED

Part B Payment	OPPS Payment	Other Payment
Independent ESRD Limit:	\$63.38	
ESRD Effective Date:	04/01/2005	
Vaccine Limit:		
DME Infusion Limit:		
Blood Limit:		

©Copyright Ingenix, Inc. 2005. All Rights Reserved. CPT only © 2004 American Medical Association. All Rights Reserved.
CPT is a registered trademark of the American Medical Association.